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A bs tr ac t
Background
Immunosuppressive regimens with the fewest possible toxic effects are desirable for 
transplant recipients. This study evaluated the efficacy and relative toxic effects of 
four immunosuppressive regimens.
Methods
We randomly assigned 1645 renal-transplant recipients to receive standard-dose cy-
closporine, mycophenolate mofetil, and corticosteroids, or daclizumab induction, my-
cophenolate mofetil, and corticosteroids in combination with low-dose cyclosporine, 
low-dose tacrolimus, or low-dose sirolimus. The primary end point was the estimated 
glomerular filtration rate (GFR), as calculated by the Cockcroft–Gault formula, 
12 months after transplantation. Secondary end points included acute rejection and 
allograft survival.
Results
The mean calculated GFR was higher in patients receiving low-dose tacrolimus 
(65.4 ml per minute) than in the other three groups (range, 56.7 to 59.4 ml per min-
ute). The rate of biopsy-proven acute rejection was lower in patients receiving low-dose 
tacrolimus (12.3%) than in those receiving standard-dose cyclosporine (25.8%), low-
dose cyclosporine (24.0%), or low-dose sirolimus (37.2%). Allograft survival differed 
significantly among the four groups (P = 0.02) and was highest in the low-dose tacro-
limus group (94.2%), followed by the low-dose cyclosporine group (93.1%), the stan-
dard-dose cyclosporine group (89.3%), and the low-dose sirolimus group (89.3%). 
Serious adverse events were more common in the low-dose sirolimus group than in the 
other groups (53.2% vs. a range of 43.4 to 44.3%), although a similar proportion of 
patients in each group had at least one adverse event during treatment (86.3 to 90.5%).
Conclusions
A regimen of daclizumab, mycophenolate mofetil, and corticosteroids in combination 
with low-dose tacrolimus may be advantageous for renal function, allograft survival, 
and acute rejection rates, as compared with regimens containing daclizumab induc-
tion plus either low-dose cyclosporine or low-dose sirolimus or with standard-dose 
cyclosporine without induction. (ClinicalTrials.gov number, NCT00231764.)
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Despite improved short-term out-come in renal transplantation, 3 to 5% of allografts per year are still lost; the lead-
ing causes are long-term allograft nephropathy and 
death with a functioning allograft.1 As patients 
have fewer acute rejection episodes, adverse events 
associated with long-term immunosuppression 
have become increasingly evident. Accordingly, re-
ducing the toxic effects of immunosuppressive 
regimens has become a major goal in the treatment 
of transplant recipients.
Cyclosporine, a calcineurin inhibitor in use for 
many years, is still the basis of many immunosup-
pressive regimens because of its clinical success. 
However, standard recommended doses are asso-
ciated with nephrotoxicity, resulting in long-term 
renal dysfunction,2 hypertension, and hyperlipid-
emia.3-6 In one report, virtually all 99 recipients of 
kidney–pancreas transplants who received cyclo-
sporine-based immunosuppression had nephro-
toxicity 10 years after transplantation, with the 
median onset of the first lesion at 6 months.7 Tac-
rolimus, a more recently introduced calcineurin 
inhibitor, is reportedly more effective than cyclo-
sporine at improving allograft survival and pre-
venting acute rejection at 1 year.8 However, at 
currently recommended doses, tacrolimus shares 
many side effects with cyclosporine, including 
nephrotoxicity, neurotoxicity, infectious complica-
tions, and disturbances in lipid metabolism.9,10 
Sirolimus, recently introduced, is as effective as 
cyclosporine11,12 but is associated with delayed 
wound healing,13 formation of lymphoceles,14 and 
an increased incidence of several other adverse 
events (including hyperlipidemia,11 thrombocyto-
penia,12 and diarrhea), as compared with cyclo-
sporine.12
Accordingly, immunosuppressive regimens that 
would permit dose reductions of these calcineu-
rin inhibitors and sirolimus would be attractive, 
provided that adequate immunosuppression and 
acceptable rates of acute rejection were preserved. 
The Efficacy Limiting Toxicity Elimination (ELITE)–
Symphony study was initiated to assess whether a 
mycophenolate mofetil–based regimen would per-
mit the administration of lower doses of adjunct 
immunosuppressive agents (e.g., cyclosporine, tac-
rolimus, and sirolimus), yet still maintain an ac-
ceptable rate of acute rejection and a more favor-
able tolerability profile. Unlike many other studies 
that have evaluated immunosuppressive regimens, 
our trial used low-dose maintenance levels of cy-
closporine, tacrolimus, or sirolimus from the day 
of transplantation. The study design was based on 
standard clinical procedures in common use in-
ternationally, a factor that allowed many patients 
to meet the criteria for study entry.
Me thods
Study Design and Patients
We carried out a 12-month, prospective, random-
ized, open-label, multicenter study in four paral-
lel groups of adult renal-transplant recipients in 
compliance with the provisions of the Declaration 
of Helsinki and Good Clinical Practice guidelines. 
All patients provided written informed consent and 
could withdraw from the study at any time.
The trial was proposed and designed by the 
first and last authors, who obtained funding and 
ran the trial, along with steering committee mem-
bers, who had complete access to the data for re-
view of the analysis and controlled the decision to 
publish. Funding for the study was provided by 
Hoffmann–La Roche, which had advisory input 
into the study design, collected the data, moni-
tored the conduct of the study, performed the 
statistical analyses, and coordinated the writ-
ing of the manuscript with all authors. The first 
author had access to the complete study data, and 
vouches for the veracity and completeness of the 
data and the data analyses. Representatives of 
Hoffmann–La Roche had the opportunity to re-
view and comment on all versions of the manu-
script.
Patients between the ages of 18 and 75 years 
who were scheduled to receive a single-organ renal 
transplant from either a living donor or a deceased 
donor were eligible. Patients receiving a second 
renal transplant were eligible, provided that the 
first allograft was not lost owing to acute rejection 
within the first year after transplantation. Exclu-
sion criteria included the need for treatment with 
azathioprine, methotrexate or cyclophosphamide, 
polyclonal or monoclonal antilymphocyte anti-
bodies, basiliximab, or any investigational drug; 
a current or historic panel-reactive antibody titer 
of more than 20%; a positive cross-match; a cold-
ischemia time of more than 30 hours for the al-
lograft; receipt of an allograft from a deceased 
donor without a heartbeat; a gastrointestinal dis-
order that might interfere with the ability to ab-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAT DE BARCELONA CRAI on July 3, 2014. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 357;25 www.nejm.org december 20, 20072564
sorb oral medication; a history of cancer, except 
successfully treated, localized nonmelanocytic skin 
cancer; active peptic ulcer; evidence of active liver 
disease; severe anemia, leukopenia, or thrombo-
cytopenia; the receipt of a new investigational drug 
within the previous 3 months; and previous treat-
ment with daclizumab or basiliximab.
Patients were randomly assigned in a 1:1:1:1 
ratio to one of four treatment groups: the stan-
dard-dose cyclosporine group, which received a 
standard dose of cyclosporine (Neoral or Sandim-
mune, Novartis), mycophenolate mofetil (CellCept, 
Hoffmann–La Roche), and corticosteroids; the low-
dose cyclosporine group, which received dacliz-
umab (Zenapax, Hoffmann–La Roche) during the 
first 2 months after transplantation and a low dose 
of cyclosporine, mycophenolate mofetil, and cor-
ticosteroids; the low-dose tacrolimus group, which 
received daclizumab during the first 2 months af-
ter transplantation and a low dose of tacrolimus 
(Prograf, Astellas Pharma), mycophenolate mofetil, 
and corticosteroids; and the low-dose sirolimus 
group, which received daclizumab during the first 
2 months after transplantation and a low dose 
of sirolimus (Rapamune, Wyeth), mycophenolate 
mofetil, and corticosteroids.
Randomization was stratified according to the 
local participating center and the presence or ab-
sence of a donor with expanded criteria.15 Patients 
underwent randomization before scheduled renal 
transplantation with the use of a centralized in-
teractive voice-response system (ClinIT). A mini-
mization algorithm was used to optimize the bal-
ance of characteristics of patients in study groups, 
overall and across the strata.
Intravenous daclizumab was infused during a 
period of 15 to 20 minutes at a dose of 2 mg per 
kilogram of body weight within 24 hours before 
transplantation, followed by four doses of 1 mg 
per kilogram every 2 weeks. The first doses of 
mycophenolate mofetil, cyclosporine, tacrolimus, 
and sirolimus were administered within 24 hours 
before or after transplantation. All groups received 
oral mycophenolate mofetil at a dose of 2 g per 
day. In the standard-dose cyclosporine group, the 
initial oral dose of 3 to 5 mg per kilogram twice 
daily was adjusted to achieve a target trough 
level of 150 to 300 ng per milliliter for the first 
3 months and 100 to 200 ng per milliliter there-
after. Target trough cyclosporine levels in the low-
dose cyclosporine group were 50 to 100 ng per 
milliliter throughout the study; the initial oral 
dose was 1 to 2 mg per kilogram twice daily. In 
the low-dose tacrolimus group, the initial dose of 
oral tacrolimus of 0.1 mg per kilogram per day 
divided into two daily doses was adjusted to 
achieve a target trough level of 3 to 7 ng per mil-
liliter. In the low-dose sirolimus group, patients 
received oral sirolimus at a dose of 9 mg per day 
for 3 days and 3 mg per day thereafter, adjusted 
to achieve trough levels of 4 to 8 ng per milliliter. 
All patients received intraoperative and mainte-
nance corticosteroids according to the practice at 
the center. The minimum maintenance cortico-
steroid doses were 20 mg of prednisone (or the 
equivalent) for the first 2 weeks after transplan-
tation, 15 mg from week 3 to week 8, 10 mg from 
week 9 until the end of month 4, and 5 mg there-
after.
Blood levels of cyclosporine, tacrolimus, and 
sirolimus were measured with the use of locally 
available assays. On the basis of information from 
60 of 83 sites, the most commonly used assays 
were TDx (Abbott Diagnostics) for cyclosporine 
(used at 33.3% of sites), IMx (Abbott Diagnostics) 
for tacrolimus (used by 65.0%), and high-perfor-
mance liquid chromatography with ultraviolet de-
tection for sirolimus (used by 61.7%).
Efficacy
The primary end point was the estimated glomer-
ular filtration rate (GFR) 12 months after trans-
plantation, calculated from serum creatinine 
measures with the use of the Cockcroft–Gault 
formula.16 Secondary efficacy end points included 
renal function as indicated by the calculated GFR 
during the course of the study, measured GFR at 
12 months, acute rejection, overall survival and al-
lograft survival at 6 and 12 months, time to the 
first episode of acute rejection, the frequency of 
treatment failure during the first 12 months, and 
the incidence of delayed allograft function. Treat-
ment failure was defined as the occurrence of any 
of the following: the use of additional immuno-
suppressive medication, the discontinuation of any 
study medication for more than 14 consecutive days 
or more than 30 cumulative days, allograft loss, 
or death.
Safety
Safety was evaluated by clinical assessment includ-
ing vital signs and laboratory analyses designed 
to determine the incidence of adverse events, op-
portunistic infections, cancer, and death through-
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out the study; the incidence of failure to achieve 
primary closure of the transplant surgical wound 
at 2 weeks; and the formation of lymphoceles re-
quiring intervention within 6 months after trans-
plantation.
Statistical Analysis
The original protocol called for the enrollment of 
1300 patients. In an amendment to the protocol, 
this number was increased to 1760 patients (440 
per group) to provide a power of 80% to detect a 
difference of 6.5 ml per minute in GFR in one 
group with respect to the others in a global test, 
a value that was considered to be clinically rele-
vant by the study’s steering committee. To calcu-
late the GFR, a last-observation-carried-forward 
method was used for serum creatinine and weight, 
and 10 ml per minute was imputed for missing 
values.
The primary method used to compare the study 
groups was an analysis of variance including fac-
tors for treatment, center, and donors with ex-
panded criteria and other factors. Since the model, 
even after variable transformations, markedly vio-
lated the assumptions for normality (as judged 
by the study statistician after inspection of diag-
nostic plots and by the rejection of normality as-
sumption with the use of the Shapiro–Wilk test 
at the 10% level), we performed overall group com-
parisons with the use of the Kruskal–Wallis test, 
followed by pairwise comparisons with the Wil-
coxon rank-sum test in case of significance at the 
5% level. Time to biopsy-proven acute rejection, 
allograft loss, treatment failure, and death were 
analyzed with the use of the Kaplan–Meier meth-
od, and group differences were assessed by the 
log-rank test.
Groups of patients that underwent analysis in-
cluded a safety population (patients who received 
at least one dose of a study drug) and an inten-
tion-to-treat population (patients who received at 
least one dose of a study drug and underwent 
transplantation). Patients who were prematurely 
withdrawn from the study were followed for data 
collection whenever possible.
The incidence of all adverse events and serious 
adverse events are reported as frequencies in the 
safety population. However, the number of pa-
tients at risk for an event varied with time, owing 
to the variation in premature withdrawal in the 
study groups. Therefore, additional Kaplan–Meier 
analyses were performed for selected adverse 
events known to be associated with immunosup-
pressive drugs,9,12,14 including new-onset diabetes 
after transplantation, diarrhea, the formation of 




From November 2002 to November 2004, a total 
of 1645 patients from 83 sites in 15 countries un-
derwent randomization (Fig. 1). Although the re-
cruitment target of 1760 was not met by the end 
of the planned enrollment period, the duration 
of recruitment was not extended for operational 
reasons. The groups were well balanced with re-
spect to demographic, clinical, and donor–recipi-
ent characteristics, with no significant between-
group differences (Table 1). Withdrawal from 
assigned treatment ranged from 20.0% in the low-
dose tacrolimus group to 48.9% in the low-dose 
sirolimus group (Fig. 1). In all groups, treatment 
failure was the main reason for withdrawal. The 
use of additional immunosuppressive drugs (in 
7.5 to 30.3% of patients, depending on the group) 
and the discontinuation of a study drug (in 16.4 
to 24.6% of patients, depending on the group) were 
the main categories of treatment failure in the four 
study groups. Acute rejection was not explicitly in-
cluded as one of the possible reasons for treatment 
failure.
Target trough levels for immunosuppression 
were generally met (Fig. 2). Mean (±SD) levels 
were mainly at the upper end of the target range. 
Mean daily doses of corticosteroids (or prednisone 
equivalent) during the first year were 16.3±13.1 
mg (in the standard-dose cyclosporine group), 
14.2±14.2 mg (in the low-dose cyclosporine group), 
13.5±10.0 mg (in the low-dose tacrolimus group), 
and 17.7±14.1 mg (in the low-dose sirolimus 
group). These doses were higher in the standard-
dose cyclosporine group and the low-dose siroli-
mus group than in the low-dose tacrolimus group 
(P = 0.01 and P<0.001, respectively) and higher in 




Twelve months after transplantation, renal func-
tion differed significantly among the four groups 
(P<0.001 for the overall group comparison). The 
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estimated GFR was higher in the low-dose tacro-
limus group than in the other study groups 
(P<0.001 for the comparisons with the standard-
dose cyclosporine group and the low-dose siroli-
mus group and P = 0.001 for the comparison with 
the low-dose cyclosporine group) (Table 2). The 
mean estimated GFR remained relatively stable 
from about 8 weeks onward.
Acute Rejection
At 6 and 12 months, the incidence of biopsy-proven 
acute rejection (excluding borderline cases) in the 
low-dose tacrolimus group was approximately half 
those in the standard-dose cyclosporine group and 
the low-dose cyclosporine group and approximate-
ly one third that in the low-dose sirolimus group 
(P<0.001 for all pairwise comparisons with low-
39p6
1645 Underwent randomization
2072 Patients underwent assessment
427 Were excluded
236 Did not meet inclusion
criteria
87 Declined to participate
35 Had logistical reasons
36 Enrolled in another study
33 Had other reason
410 Were assigned to receive
 standard-dose cyclosporine
20 Did not receive treatment
or did not undergo trans-
plantation
390 Received treatment and
transplantation
413 Were assigned to receive
low-dose cyclosporine
14 Did not receive treatment
or did not undergo trans-
plantation
399 Received treatment and
transplantation
411 Were assigned to receive
low-dose tacrolimus
10 Did not receive treatment
or did not undergo trans-
plantation
401 Received treatment and
transplantation
411 Were assigned to receive
low-dose sirolimus
12 Did not receive treatment
or did not undergo trans-
plantation
399 Received treatment and
transplantation
116 Withdrew from treatment
12 Had adverse event or
coexisting illness
62 Had treatment failure
8 Received a prohibited 
medication
3 Had a compliance
violation
5 Were lost to follow-up
8 Died
5 Withdrew consent
13 Had other reason
110 Withdrew from treatment
2 Had unknown reason
7 Had adverse event or
 coexisting illness
61 Had treatment failure
8 Received a prohibited 
medication
4 Had a compliance
violation
7 Were lost to follow-up
5 Died
2 Withdrew consent
14 Had other reason
80 Withdrew from treatment
1 Had unknown reason
9 Had adverse event or
coexisting illness
34 Had treatment failure
1 Received a prohibited 
medication
6 Had a compliance
violation
6 Were lost to follow-up
9 Died
6 Withdrew consent
8 Had other reason
195 Withdrew from treatment
31 Had adverse event or
 coexisting illness
109 Had treatment failure
17 Received a prohibited 
medication
4 Had a compliance
violation
5 Were lost to follow-up
6 Died
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Figure 1. Enrollment and Outcomes.
The safety population, which consisted of all patients who received at least one dose of a study drug, included 384 patients in the stan-
dard-dose cyclosporine group, 408 patients in the low-dose cyclosporine group, 403 patients in the low-dose tacrolimus group, and 380 
patients in the low-dose sirolimus group. All patients who received treatment and underwent transplantation were included in the inten-
tion-to-treat population.
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dose tacrolimus) (Fig. 3A and Table 2). At 12 
months, the proportions of patients with clinical-
ly suspected, treated episodes of acute rejection 
were similar to those of biopsy-proven acute rejec-
tion (P<0.001 for all pairwise comparisons with 
low-dose tacrolimus) (Table 2).
Overall Survival and Allograft Survival
Allograft survival in the low-dose tacrolimus group 
was significantly higher than in the standard-dose 
cyclosporine group and the low-dose sirolimus 
group (P = 0.007 for both comparisons) (Table 2 
and Fig. 3B). Overall survival rates for patients were 
more than 96% in all groups without significant 
differences (Table 2).
Treatment Failure
Treatment failure was lowest in the low-dose tac-
rolimus group (12.2%) and highest in the low-
dose sirolimus group (35.8%, P<0.001) (Table 2). 














Age (yr) 45.9±13. 8 47.2±13.5 45.4±14.7 44.9±14.5
Male sex (%) 62.3 66.4 65.8 66.7
Race (%)†
White 92.1 92.2 94.0 94.2
Black 2.1 2.3 1.0 1.3
Asian 1.3 0.8 0.7 0.5
Other 4.6 4.8 4.2 4.0
Cause of end-stage renal disease (%)
Glomerulonephritis 29.7 26.1 26.9 28.8
Diabetes mellitus 6.9 9.0 8.5 7.8
Pyelonephritis or interstitial nephritis 10.0 8.0 9.2 11.5
Polycystic kidney disease 12.8 12.0 15.5 11.3
Uncertain 19.5 24.3 20.7 19.0
Other 20.5 20.3 19.2 21.3
Missing data 0.5 0.3 0 0.3
Type of donor (%)
Deceased 65.6 64.2 62.8 64.2
Living related 28.5 26.8 31.7 30.1
Living unrelated 5.9 8.8 5.2 5.8
Donors with expanded criteria (%)‡ 16.9 18.0 17.7 19.3
Donor age (yr) 44.6±15.9 46.2±15.1 45.2±15.5 46.0±14.8
Antigen mismatches — A, B, and DR (no.) 2.95±1.54 3.05±1.50 2.87±1.55 2.99±1.49
Panel-reactive antibody >0% — most recent  
assessment (%)
21.0 22.1 19.9 17.1
Cold-ischemia time — deceased donors only (hr) 16.6±5.5 16.8±5.2 16.5±5.7 16.0±5.8
Cytomegalovirus serologic status — donor posi-
tive, recipient negative (%)
13.6 13.5 12.7 15.5
* Plus–minus values are means ±SD. Between-group differences for demographic and clinical characteristics were not 
significant.
† Race was determined by the investigator.
‡ The percentage is that of deceased donors only. Expanded criteria for deceased donors included an age of more than 
60 years or an age of more than 50 years and at least two of the following factors: cerebovascular accident as the cause 
of death, hypertension, or a serum creatinine level of more than 1.5 mg per deciliter (133 μmol per liter).
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Treatment failure as a result of discontinuation of 
any assigned immunosuppressive agent for more 
than 14 consecutive days leading to withdrawal 
was 4.5% in the low-dose tacrolimus group, as 
compared with 5.1 to 6.8% in the other study 
groups. Treatment failure as a result of the use of 
additional maintenance immunosuppressive med-
ication was 1.5% in the low-dose tacrolimus group, 
as compared with 6.0 to 14.8% in the other study 
groups. Overall, the rate of treatment failure was 
44.0% in patients who had acute rejection, as com-
pared with 13.7% in those who did not have acute 
rejection in the intention-to-treat population.
Delayed Allograft Function
Among recipients of a kidney from a deceased do-
nor, the incidence of delayed allograft function at 
2 weeks (defined as persistent oliguria, a decrease 
in the serum creatinine level of less than 0.5 mg 
per deciliter within 24 hours after transplantation, 
or the institution of dialysis) was lower in the low-
dose sirolimus group than in the low-dose tacro-
limus group (P = 0.001) (Table 2).
Safety
Serious adverse events were reported by 53.2% of 
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Figure 2. Mean Trough Levels of Cyclosporine, Tacrolimus, and Sirolimus, According to Study Group.
Kidney-transplant recipients in all four study groups were treated with mycophenolate mofetil and corticosteroids for 1 year in addition 
to the assigned study drug. Patients in the low-dose cyclosporine group, the tacrolimus group, and the sirolimus group also received  
daclizumab induction. Data are for the intention-to-treat population. Data are excluded for patients with standard-dose cyclosporine val-
ues of less than 49.0 ng per milliliter or more than 808.0 ng per milliliter, low-dose cyclosporine values of less than 29.0 ng per milliliter 
or more than 690.8 ng per milliliter, low-dose tacrolimus values of less than 2.2 ng per milliliter or more than 18.4 ng per milliliter, and 
low-dose sirolimus values of less than 2.2 ng per milliliter or more than 24.3 ng per milliliter. The dashed lines represent the upper and 
lower limits of the respective target trough levels. To convert the values for cyclosporine, tacrolimus, and sirolimus to nanomoles per  
liter, multiply by 0.83, 1.24, and 1.09, respectively. The I bars repres nt standard deviations. 
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(N = 399) P Value†
Primary end point
Mean calculated GFR — ml/min‡ 57.1±25.1 59.4±25.1 65.4±27.0 56.7±26.9 <0.001
P value for comparison with tacrolimus <0.001 0.001 Reference <0.001
Secondary end points 
Mean measured GFR — ml/min§ 63.5±25.4 65.3±26.6 69.6±27.9 64.4±28.5 0.04
P value for comparison with tacrolimus 0.01 0.10 Reference 0.02
Mean calculated GFR — ml/min¶ 46.2±23.1 50.2±23.1 54.3±23.9 47.5±26.1 <0.001
P value for comparison with tacrolimus <0.001 0.007 Reference <0.001
Acute rejection‖
At 6 mo
Biopsy-proven (excluding borderline values) — % 24.0 21.9 11.3 35.3 <0.001
P value for comparison with tacrolimus <0.001 <0.001 Reference <0.001
At 12 mo
Suspected and treated — % 32.8 29.5 17.2 43.5 <0.001
P value for comparison with tacrolimus <0.001 <0.001 Reference <0.001
Biopsy-proven (including borderline values) — % 30.1 27.2 15.4 40.2 <0.001
P value for comparison with tacrolimus <0.001 <0.001 Reference <0.001
Biopsy-proven (excluding borderline values) — % 25.8 24.0 12.3 37.2 <0.001
P value for comparison with tacrolimus <0.001 <0.001 Reference <0.001
Antibody treated — % 6.3 4.7 2.3 6.6 0.01
P value for comparison with tacrolimus 0.006 0.08 Reference 0.005
Allograft survival‖
Censored for death of patients with functioning  
allograft — %
91.9 94.3 96.4 91.7 0.02
P value for comparison with tacrolimus 0.007 0.18 Reference 0.007
Uncensored for death of patients with functioning  
allograft — %
89.3 93.1 94.2 89.3 0.02
P value for comparison with tacrolimus 0.01 0.56 Reference 0.01
Patient survival — %‖ 96.5 98.2 97.2 96.8 0.53
P value for comparison with tacrolimus 0.60 0.35 Reference 0.78
Treatment failure — %‖ 22.8 20.1 12.2 35.8 <0.001
P value for comparison with tacrolimus <0.001 0.003 Reference <0.001
Delayed allograft function (deceased donors only) — % 33.6 32.4 35.7 21.1 0.004
P value for comparison with tacrolimus 0.73 0.51 Reference 0.001
* Plus–minus values are means ±SD. P values for comparisons between each of the study groups and the low-dose tacrolimus group were 
calculated with the use of the Wilcoxon rank-sum test for end points regarding the glomerular filtration rate (GFR) and the log-rank test  
for all other end points except delayed allograft function, for which the chi-square test was used. 
† P values were calculated with the use of the Kruskal–Wallis test for the overall group comparison.
‡ The calculated GFR (with an imputation of 10 ml per minute for missing values and the last observation carried forward) was determined 
from the serum creatinine level with the use of the Cockcroft–Gault formula to calculate creatinine clearance. The number of patients with 
the last observation carried forward and imputed values for calculated GFR were 23 and 37, respectively, in the standard-dose cyclosporine 
group (15.4%), 22 and 25 in the low-dose cyclosporine group (11.8%), 19 and 24 in the low-dose tacrolimus group (10.7%), and 27 and 38 
in the low-dose sirolimus group (16.3%). 
§ The GFR was measured at 12 months mostly by the 24-hour urine method. 
¶ For the calculated GFR on the basis of abbreviated Modification of Diet in Renal Disease criteria, the following formula was used:  
estimated GFR (ml/min/1.73 m2) = 186 × (serum creatinine)−1.154 × (age)−0.203 × (0.742 if female) × (1.21 if black).
‖ Values are Kaplan–Meier estimates over time. 
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pared with 43.4 to 44.3% in the other study groups 
(P<0.05 for all comparisons and for between-
group comparisons with low-dose sirolimus). In 
a similar way, 7.8% of patients in the low-dose si-
rolimus group withdrew from treatment because 
of an adverse event or a coexisting illness, as com-
pared with 1.8 to 3.1% in the other study groups 
(Fig. 1). A similar proportion of patients in each 
group had at least one adverse event during the 
study (86.3 to 90.5%).
The most common adverse events according to 
body system for all groups were disorders of the 
blood or lymphatic systems, gastrointestinal dis-
orders, infections or infestations, and metabolism 
and nutrition disorders (Table 3).
There was a significant between-group differ-
ence in the Kaplan–Meier estimates for new-
onset diabetes after transplantation at 12 months 
(P = 0.02 for all comparisons), with the highest rate 
occurring in the low-dose tacrolimus group (Ta-
ble 3). The proportion of patients who required 
antidiabetes medication at 3 months after the on-
set of diabetes ranged from 1.0 to 2.7%, depend-
ing on the study group. The Kaplan–Meier esti-
mates for diarrhea differed significantly between 
the groups (P<0.001), with the lowest rates occur-
ring in the two cyclosporine groups. With respect 
to the formation of lymphoceles, the rates also 
differed significantly among the groups (P<0.001), 
with at least twice as many events in the low-
dose sirolimus group as in the other groups. In 
addition, the proportion of patients who had de-
layed wound healing 2 weeks after transplanta-
tion differed significantly among the study groups 
(P = 0.006 by the chi-square test), with more pa-
tients in the low-dose sirolimus group having de-
layed healing than in the other groups (Table 3).
There was a significant between-group differ-
ence in the Kaplan–Meier estimates for opportu-
nistic infections (P = 0.03) and cytomegalovirus 
infection (P = 0.003), the latter being the most 
common opportunistic infection (Table 3). Op-
portunistic infections, including cytomegalovi-
rus infection, were generally more common in 
the standard-dose cyclosporine group than in the 
other groups. Although there was no stratifi-
cation according to donor–recipient status for 
cytomegalovirus, there was no significant be-
tween-group difference in the proportion of cy-
tomegalovirus-positive donors to cytomegalovirus-
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Figure 3. Cumulative Probability of Biopsy-Proven Acute Rejection (Panel A) 
and Allograft Survival (Panel B), According to Study Group.
The number at risk at 12 months includes all patients who were not lost  
to follow-up and who had completed the 12-month visit not earlier than  
2 weeks before the end of the first year after transplantation. For the  
Kaplan–Meier estimates of event rates presented here, data for patients 
who completed the study according to protocol before the first year after 
transplantation were censored at the time of their last visit. Data for pa-
tients with borderline acute rejection were excluded from the analysis of  
biopsy-proven acute rejection. The analysis of data for patients who died 
with a functioning allograft were censored.
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Cancer developed in four to nine patients in the 
various study groups within the first 12 months 
(Table 3). There were 13 deaths in the standard-
dose cyclosporine group, and 7, 11, and 12 deaths 
in the low-dose cyclosporine group, the low-dose 
tacrolimus group, and the low-dose sirolimus 
group, respectively. Deaths were preceded by treat-
ment failure in one patient in the standard-dose 
cyclosporine group, two patients in the low-dose 
cyclosporine group, one patient in the low-dose 
tacrolimus group, and one patient in the low-
dose sirolimus group. Four deaths were caused 
by adverse events or coexisting illnesses: two in 
the standard-dose cyclosporine group and one 
each in the low-dose cyclosporine group and the 
low-dose tacrolimus group.
Discussion
The primary objective of our study was to reduce 
nephrotoxicity with the use of low doses of calci-
neurin inhibitors or sirolimus. Accordingly, the 
primary end point was renal function. Secondary 
objectives were to reduce overall toxic effects 
while maintaining efficacy in terms of acute re-
jection, overall survival of patients, and allograft 
survival.
In an initial trial conducted by members of our 
group, the avoidance of calcineurin inhibitors with 
the use of mycophenolate mofetil, daclizumab, and 
corticosteroids resulted in excellent rates of over-
all and allograft survival at 12 months (97% and 
96%, respectively) but had an unacceptably high 
rate of biopsy-proven acute rejection (53%).17 Ac-
cordingly, the subsequent Cyclosporine Avoid-
ance Eliminates Serious Adverse Renal Toxicity 
(CAESAR) study was designed with the addition 
of low-dose cyclosporine, either continuously 
administered or tapered and withdrawn at 4 to 
6 months.18
Our findings represent a further development 
of strategies for reducing the burden of side ef-
fects. With the addition not only of low-dose cy-
closporine but also of either low-dose tacrolimus 
or low-dose sirolimus to the combination of da-
clizumab, mycophenolate mofetil, and corticoste-
roids, our study aimed to reduce the rate of bi-
opsy-proven acute rejection from the previously 
reported rate of 53%.17 In both the CAESAR 
study18 and our study, patients receiving low-dose 
cyclosporine had rates of biopsy-proven acute rejec-
tion and of mean GFR at 12 months similar to 
those of patients receiving standard-dose cyclospo-
rine. Thus, reduced doses of cyclosporine did not 
improve renal function, and further reductions in 
cyclosporine exposure (to trough levels <50 ng per 
milliliter) would probably not provide adequate 
immunosuppression. However, it is possible that 
optimizing the exposure to mycophenolate mofetil 
through therapeutic drug monitoring could im-
prove rates of acute rejection and allograft func-
tion in a cyclosporine-based regimen.
In our study, the low-dose sirolimus regimen 
resulted in rates of biopsy-proven acute rejection 
that were higher than those in the other regimens, 
and there was no improvement in renal function, 
as compared with the cyclosporine-containing 
regimens. This latter result contrasts with the 
findings of Flechner et al.,19 which showed no 
significant differences in efficacy but significantly 
better rates of renal function at 2 years and lower 
rates of long-term allograft nephropathy in pa-
tients receiving standard-dose sirolimus than in 
those receiving standard-dose cyclosporine, both 
in combination with basiliximab induction, my-
cophenolate mofetil, and corticosteroids. However, 
the study by Flechner et al. was a single-center 
study involving only 61 patients who received 
higher doses of sirolimus (trough level, 10 to 12 ng 
per milliliter during the first 6 months and 5 to 
10 ng per milliliter thereafter) than did patients 
in our study (trough level, 4 to 8 ng per milliliter). 
It is possible that the sirolimus dose in our study 
was too low to provide adequate immunosuppres-
sion in the period immediately after transplanta-
tion. Nonetheless, biopsy-proven acute rejection 
did not reach the 53% level seen with the proto-
col calling for the administration of daclizumab, 
mycophenolate mofetil, and corticosteroids.17 
Therefore, the addition of low-dose sirolimus had 
some efficacy, even though it did not eliminate 
side effects. It is also possible that the combina-
tion of sirolimus and mycophenolate mofetil is 
inadequate for preventing acute rejection. Two 
multicenter studies in renal-transplant patients 
receiving standard doses of sirolimus, mycophe-
nolate mofetil, and corticosteroids, used in com-
bination with interleukin-2 receptor antibody in-
duction, were recently terminated early because 
of an increased risk of rejection.20
New-onset diabetes is an important concern 
after organ transplantation and appears to be re-
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Blood or lymphatic 33.3 33.6 36.2 36.1
Anemia 18.5 17.4 17.1 25.0
Leukopenia 10.2 10.1 13.4 10.3
Gastrointestinal 33.3 32.6 41.4 34.7
Abdominal pain 3.9 4.2 5.2 2.6
Constipation 6.5 5.2 6.7 6.1
Diarrhea 15.6 13.0 25.3 19.5
Vomiting 4.7 3.9 5.5 2.6
General or site of drug administration 23.2 22.6 22.1 27.4
Peripheral edema 12.0 12.5 11.2 13.2
Pyrexia 4.4 5.6 5.0 9.0
Opportunistic infection† 26.0 22.8 19.9 20.3
Candida 7.6 4.7 3.0 5.0
Cytomegalovirus 14.3 11.0 9.7 6.1
Herpes simplex virus 5.5 3.7 4.5 6.1
Other infection or infestation 54.2 50.5 52.4 52.6
Nasopharyngitis 5.7 7.8 7.9 4.0
Pneumonia 4.7 1.2 3.2 5.0
Urinary tract infection 28.4 23.8 23.6 23.2
Injury, poisoning, or procedural complication 32.6 27.2 26.8 31.1
Complications of transplanted kidney 6.3 6.6 5.2 4.5
Delayed wound healing at week 2 10.8 11.0 9.4 16.6
Lymphocele 6.3 5.6 4.0 11.6
Laboratory investigation 24.5 24.8 26.8 25.5
Increased blood creatinine level 7.8 6.9 8.2 7.9
Metabolism or nutrition 46.1 38.2 38.0 47.1
Diabetes mellitus 6.0 4.2 8.4 6.6
Hypercholesterolemia 10.4 9.8 4.5 10.3
Hyperglycemia 4.4 2.9 4.7 5.0
Hyperlipidemia 14.8 12.5 9.9 15.8
Hypertriglyceridemia 4.2 3.7 3.5 6.8
Hyperuricemia 5.7 5.6 4.5 1.6
Hypophosphatemia 3.1 3.7 3.5 5.5
Nervous system 13.0 9.8 15.9 9.0
Headache 5.0 4.2 5.5 3.2
Renal or urinary 28.7 27.9 29.8 29.0
Hematuria 5.2 4.9 5.2 4.2
Proteinuria 2.3 2.0 5.0 5.3
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Vascular 28.9 22.6 23.6 29.2
Hypertension 14.3 11.5 12.9 11.8
Serious adverse event
Blood or lymphatic 1.8 3.4 3.0 4.2
Cardiac 3.9 3.7 3.2 2.9
Gastrointestinal 3.9 5.6 8.2 7.6
General or site of drug administration 1.3 2.5 3.0 5.3
Immune system 1.6 2.7 1.5 3.4
Infection or infestation 15.1 14.0 14.9 20.5
Injury, poisoning, or procedural complication 11.2 8.8 9.7 11.1
Laboratory investigation 3.7 2.9 6.2 5.5
Metabolism or nutrition 2.1 2.5 3.5 3.7
Renal or urinary‡ 12.0 13.0 11.2 7.9
Respiratory, thoracic, or mediastinal 2.3 1.0 1.7 2.9
Surgical wound 1.3 2.5 2.5 2.4
Vascular 5.7 3.9 4.2 10.3
Cancer§ 0.5 0.7 1.0 2.1
number of patients
Oral mucosa 1 0 0 1
Kaposi’s sarcoma 1 1 0 0
Prostate 0 0 1 0
Transitional-cell 0 1 0 0
Renal-cell 0 1 2 1
Lung
Non–small-cell 0 0 0 1
Small-cell 0 0 0 1
Breast 0 0 0 1
Colon 0 0 0 1
Cerebral lymphoma 0 0 1 0
Non-Hodgkin’s lymphoma
T-cell 0 0 0 1
B-cell 0 0 0 1
Post-transplantation lymphoproliferative  
disorder
0 0 0 1
Skin
Basal-cell 2 1 3 0
Squamous-cell 1 0 1 0
Ovarian 0 0 0 1
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lated to the use of immunosuppressive drugs that 
impair glucose tolerance, such as tacrolimus and 
corticosteroids. Given the superior rates of biop-
sy-proven acute rejection associated with the tac-
rolimus regimen in our study, it may be possible 
to reduce the risk of new-onset diabetes after 
transplantation further by a reduction in the 
exposure to corticosteroids. For example, in a 
6-month trial involving 538 renal-transplant re-
cipients, those receiving tacrolimus, mycopheno-
late mofetil, and daclizumab had a significantly 
lower incidence of new-onset diabetes after trans-
plantation than did those receiving tacrolimus, 
mycophenolate mofetil, and corticosteroids (0.4% 
vs. 5.4%, P = 0.003).21
In conclusion, in our study involving kidney-
transplant recipients, treatment for 12 months 
with a regimen containing daclizumab, mycophe-
nolate mofetil, corticosteroids, and low-dose tac-
rolimus provided adequate immunosuppression 
with better renal function and less acute rejection, 
as compared with daclizumab induction plus low-
dose cyclosporine or low-dose sirolimus-contain-
ing regimens or to a regimen containing standard-
dose cyclosporine without daclizumab induction. 
In addition, the low-dose tacrolimus regimen pro-
vided better allograft survival than did regimens 
with standard-dose cyclosporine or low-dose siro-
limus.
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Kaplan–Meier estimate of selected events¶
New-onset diabetes after transplantation 
(P = 0.02)
6.4 4.7 10.6 7.8
Use of antidiabetes medication (P = 0.37)‖ 1.3 1.5 2.7 1.0
Diarrhea (P<0.001) 17.9 14.4 27.4 24.0
Lymphocele formation (P<0.001)** 7.0 6.8 4.0 15.8
Opportunistic infection (P = 0.03) 33.0 28.1 26.3 26.6
Cytomegalovirus (P = 0.003) 15.3 11.5 10.2 6.5
* Patients were included in the safety analysis if they received at least one dose of a study drug. Listed are the most 
common adverse events according to body system (occurring in ≥10% of patients in any study group) and as individ-
ual types of events (occurring in ≥5% of patients in any study group). Serious adverse events are listed if they oc-
curred in at least 1% of patients in any study group. 
† Reports of occurrence of opportunistic infections were solicited rather than spontaneously reported by patients.
‡ Acute rejection, including its consequences, was not reported as an adverse event.
§ Included are cancers of the blood and lymphatic systems that were not reported as adverse events elsewhere. One pa-
tient in the low-dose sirolimus group had both post-transplantation lymphoproliferative disorder and colon cancer.
¶ Kaplan–Meier estimates account for the variation in the number of patients at risk after premature withdrawal from 
the study. Overall group comparisons were calculated with the use of the log-rank test. The application of the Kaplan–
Meier method for such events was defined at the time of analysis after the steering committee discovered that drop-
out rates differed substantially among the four groups.
‖ The use of antidiabetes medication 3 months after the diagnosis of new-onset diabetes after transplantation was re-
ported.
** The formation of lymphoceles occurred within 6 months after treatment.
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